Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Trial Profile

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 06 Nov 2019 According to an AstraZeneca media release, data from this trial will be presented at the upcoming 2019 American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, December 7-10.
    • 30 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2021.
    • 17 Dec 2018 Results of population pharmakoinetics of Acalabrutinib and its Active Metabolite using data from this and other 12 studies, published in the Clinical Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top